Algert Global’s BioAtla BCAB Stock Holding History

Algert Global’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-420	Closed	-$36K	–	1133
2023 Q3	$36K	Hold	420	–	–	﹤0.01%	1078
2023 Q2	$63K	Buy	420 +109	+35%	+$18.7K	﹤0.01%	1051
2023 Q1	$42K	Buy	+311	New	+$56K	﹤0.01%	1108

Other funds holding BCAB

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Algert Global's BCAB Position: Q4 2023 in Review

Algert Global sold out of BioAtla (BCAB) in Q4 2023, closing a stake of 420 shares — an estimated $36K sold.

Algert Global first reported a position in BCAB in Q1 2023 and held it in 3 quarters. The position peaked at $63K in Q2 2023. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2023.

Algert Global reported no remaining BioAtla position as of Q4 2023 after selling out during the quarter.
Algert Global sold 420 BioAtla shares in Q4 2023, an estimated $36K.
Algert Global first reported a position in BioAtla in Q1 2023 and held it in 3 quarters.
Algert Global's BioAtla position peaked at $63K in Q2 2023.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2023.

Based on Algert Global's 13F filing for Q4 2023, filed 14 Feb 2024.